FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094419523> ?p ?o ?g. }

• W3094419523 endingPage "S177" @default.
• W3094419523 startingPage "S177" @default.
• W3094419523 abstract "Predicting the risk of early distant brain failure (DBF) is a useful and demanding resource for management decisions in patients who are candidates to local treatment of brain metastasis. This study aims to analyze the correlation between circulating tumor cells (CTC) and brain disease control after stereotactic radiotherapy/radiosurgery (SRT) for brain metastasis of breast cancer (BMBC). Prospective assessment of the number of CTC before (CTC1) and 4-5 weeks after (CTC2) SRT for BMBC and its relations with the number of suggestive lesions of BMBC (NL). In this analysis, final results of the 39 enrolled patients for the study between November 2016 and February 2018 are reported. Distant brain failure-free survival (DBFFS), the primary endpoint, diffuse distant brain failure-free survival (D-DBFFS), defined as progression with more than 4 new BMBC or meningeal carcinomatosis, and overall survival (OS) were estimated by Kaplan-Meier method. Log-rank statistics were used to identify prognostic factors affecting DBFFS and OS. Competing risk analysis for DBFSS was performed. For multivariate analysis, a Cox proportional model was applied. The median age at SRT was 54 years. Immunophenotype was HER2-positive in 51%, luminal B in 31% and triple negative in 18% of patients. CTC were detected in all 39 patients before SRT and the median CTC1 was 2 CTC/mL. After SRT, CTC was detected in 34 of 35 patients (4 deaths between CTC1 and CTC2) and the median CTC2 was 2.33 CTC/mL. With a median follow-up of 16.6 months, there were 15 patients with DBF, being 6 with diffuse distant brain failure (D-DBF), and 16 deaths. The median DBFFS, D-DBFFS and OS were 15.3, 14.1 and 19.5 months, respectively. The cumulative incidence, with death as competing risk factor, of DBF at 6 months was 40% in patients with CTC1 ≤0.5 and 8.82% in patients with CTC1 >0.5 (p = 0.007) and of D-DBF at 6 months was 40% in patients with CTC1 ≤0.5 and 0 in patients with CTC1 >0.5 (p = 0.005) and 25% in patients with NL/CTC1 >6.8 and 2.65% with NL/CTC1 ≤6.8 (p = 0.063). On multivariate analysis, DBFSS was inferior in patients with CTC1 ≤0.5 CTC/mL (HR 8.27, 95% CI 2.12-32.3; p = 0.002) and superior in patients with HER2-positive (HR 0.128, 95% CI 0.025-0.534; p = 0.013), D-DBFSS was inferior in patients with CTC1 ≤0.5 CTC/mL (HR 10.22, 95% CI 1.99-52.41; p = 0.005) and OS was superior in patients with immunophenotypes HER2-positive (HR 0.073, 95% CI 0.018-0.288; p<0.0001) and luminal B (HR 0.224, 95% CI 0.062-0.816; p = 0.023) and in patients with NL/CTC1 ≤2.2 (HR 0.159, 95% CI 0.05-0.505; p = 0.002). CTC were detectable in almost all patients with BMBC. CTC1 was an independent prognostic factor of DBFFS and D-DBFFS and NL/CTC1 was independent prognostic factor of OS and NL/CTC1 was a potential prognostic factor of D-DBF at 6 months. These data suggest that CTC1 and NL/CTC1 may be a role as a biomarker of early D-DBF, helping define the timing and type of salvage radiotherapy in order to optimize the control of BMBC (NCT02941536)." @default.
• W3094419523 created "2020-10-29" @default.
• W3094419523 creator A5013207435 @default.
• W3094419523 creator A5020253636 @default.
• W3094419523 creator A5022870772 @default.
• W3094419523 creator A5024791362 @default.
• W3094419523 creator A5029097153 @default.
• W3094419523 creator A5036920872 @default.
• W3094419523 creator A5043803747 @default.
• W3094419523 creator A5044861895 @default.
• W3094419523 creator A5044984109 @default.
• W3094419523 creator A5056713913 @default.
• W3094419523 creator A5064525985 @default.
• W3094419523 creator A5065519194 @default.
• W3094419523 creator A5071671046 @default.
• W3094419523 creator A5075096799 @default.
• W3094419523 creator A5085499548 @default.
• W3094419523 date "2020-11-01" @default.
• W3094419523 modified "2023-10-09" @default.
• W3094419523 title "Final Results of a Prospective Correlative Analysis of Circulating Tumor Cells and Early Distant Brain Failure after Stereotactic Radiotherapy/Radiosurgery for Brain Metastases of Breast Cancer" @default.
• W3094419523 doi "https://doi.org/10.1016/j.ijrobp.2020.07.958" @default.
• W3094419523 hasPublicationYear "2020" @default.
• W3094419523 type Work @default.
• W3094419523 sameAs 3094419523 @default.
• W3094419523 citedByCount "1" @default.
• W3094419523 countsByYear W30944195232021 @default.
• W3094419523 crossrefType "journal-article" @default.
• W3094419523 hasAuthorship W3094419523A5013207435 @default.
• W3094419523 hasAuthorship W3094419523A5020253636 @default.
• W3094419523 hasAuthorship W3094419523A5022870772 @default.
• W3094419523 hasAuthorship W3094419523A5024791362 @default.
• W3094419523 hasAuthorship W3094419523A5029097153 @default.
• W3094419523 hasAuthorship W3094419523A5036920872 @default.
• W3094419523 hasAuthorship W3094419523A5043803747 @default.
• W3094419523 hasAuthorship W3094419523A5044861895 @default.
• W3094419523 hasAuthorship W3094419523A5044984109 @default.
• W3094419523 hasAuthorship W3094419523A5056713913 @default.
• W3094419523 hasAuthorship W3094419523A5064525985 @default.
• W3094419523 hasAuthorship W3094419523A5065519194 @default.
• W3094419523 hasAuthorship W3094419523A5071671046 @default.
• W3094419523 hasAuthorship W3094419523A5075096799 @default.
• W3094419523 hasAuthorship W3094419523A5085499548 @default.
• W3094419523 hasConcept C121608353 @default.
• W3094419523 hasConcept C126322002 @default.
• W3094419523 hasConcept C137345334 @default.
• W3094419523 hasConcept C143998085 @default.
• W3094419523 hasConcept C168563851 @default.
• W3094419523 hasConcept C188816634 @default.
• W3094419523 hasConcept C203092338 @default.
• W3094419523 hasConcept C2778164965 @default.
• W3094419523 hasConcept C2779013556 @default.
• W3094419523 hasConcept C2780387249 @default.
• W3094419523 hasConcept C38180746 @default.
• W3094419523 hasConcept C50382708 @default.
• W3094419523 hasConcept C509974204 @default.
• W3094419523 hasConcept C530470458 @default.
• W3094419523 hasConcept C71924100 @default.
• W3094419523 hasConceptScore W3094419523C121608353 @default.
• W3094419523 hasConceptScore W3094419523C126322002 @default.
• W3094419523 hasConceptScore W3094419523C137345334 @default.
• W3094419523 hasConceptScore W3094419523C143998085 @default.
• W3094419523 hasConceptScore W3094419523C168563851 @default.
• W3094419523 hasConceptScore W3094419523C188816634 @default.
• W3094419523 hasConceptScore W3094419523C203092338 @default.
• W3094419523 hasConceptScore W3094419523C2778164965 @default.
• W3094419523 hasConceptScore W3094419523C2779013556 @default.
• W3094419523 hasConceptScore W3094419523C2780387249 @default.
• W3094419523 hasConceptScore W3094419523C38180746 @default.
• W3094419523 hasConceptScore W3094419523C50382708 @default.
• W3094419523 hasConceptScore W3094419523C509974204 @default.
• W3094419523 hasConceptScore W3094419523C530470458 @default.
• W3094419523 hasConceptScore W3094419523C71924100 @default.
• W3094419523 hasIssue "3" @default.
• W3094419523 hasLocation W30944195231 @default.
• W3094419523 hasOpenAccess W3094419523 @default.
• W3094419523 hasPrimaryLocation W30944195231 @default.
• W3094419523 hasRelatedWork W1728161349 @default.
• W3094419523 hasRelatedWork W1967894062 @default.
• W3094419523 hasRelatedWork W1975088650 @default.
• W3094419523 hasRelatedWork W2066530402 @default.
• W3094419523 hasRelatedWork W2587755700 @default.
• W3094419523 hasRelatedWork W2732154237 @default.
• W3094419523 hasRelatedWork W2747510197 @default.
• W3094419523 hasRelatedWork W2800706802 @default.
• W3094419523 hasRelatedWork W3114415956 @default.
• W3094419523 hasRelatedWork W4250889109 @default.
• W3094419523 hasVolume "108" @default.
• W3094419523 isParatext "false" @default.
• W3094419523 isRetracted "false" @default.
• W3094419523 magId "3094419523" @default.
• W3094419523 workType "article" @default.